Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654964 · ClinicalTrials.gov registry record · Phase 1
Cancer Stem Cell High-Throughput Drug Screening Study
A Phase 1 study of Glioblastoma Multiforme, sponsored by Swedish Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02654964: Completed Phase 1 study of Glioblastoma Multiforme, sponsored by Swedish Medical Center.
NCT02654964 is a Phase 1 study of Glioblastoma Multiforme that has completed, run by Swedish Medical Center. The registered enrollment target is 9 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02654964, a Phase 1 study of Glioblastoma Multiforme, has completed, sponsored by Swedish Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to determine the safety of CSC/ HTS-based combination drug therapy in subjects who have GBM that has recurred or progressed following prior radiation therapy and TMZ.
Conditions Studied
Interventions
- DRUG Combination Drug Therapy
Study Locations (1)
Washington
- Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-12 |
| Est. Completion | 2023-06 |
| Phase | Phase 1 |
What the finished NCT02654964 record still lists
NCT02654964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which Combination Drug Therapy is the first listed.
NCT02654964 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT02654964 about?
NCT02654964 is a clinical study titled "Cancer Stem Cell High-Throughput Drug Screening Study". A study to determine the safety of CSC/ HTS-based combination drug therapy in subjects who have GBM that has recurred or progressed following prior radiation therapy and TMZ.
What is the current status of trial NCT02654964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-12. Estimated completion is 2023-06.
What conditions does trial NCT02654964 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT02654964?
The interventions under investigation include: Combination Drug Therapy (DRUG).
Who is sponsoring clinical trial NCT02654964?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02654964 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02654964's enrollment target sits among peer trials
9 86th of 88 higher than 2 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia